Skip to search formSkip to main contentSkip to account menu

AS 1842856

Known as: AS-1842856, AS1842856 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Cardiovascular complications are a side effect of cancer therapy, potentially through reduced blood vessel function. ONC201… 
2018
2018
FAM3B, also known as PANcreatic DERived factor (PANDER), promotes gluconeogenesis and lipogenesis in hepatocytes. However, the… 
2018
2018
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (DYRK1A) is a serine/threonine kinase that regulates diverse… 
2018
2018
Rituximab, a therapeutic anti-CD20 monoclonal antibody, is effective against B-cell malignancies, when combined with chemotherapy… 
2016
2016
ACADEMIC) Obesity is a rapidly growing epidemic in the USA and worldwide. While the molecular and cellular mechanism of obesity… 
2015
2015
Over 30% of acute myeloid leukemia (AML) patients do not respond to first-line chemotherapy, and a significant portion of… 
2015
2015
The invention discloses novel application of a FoxO1 selective inhibitor AS1842856. The novel application of a compound shown in… 
2015
2015
The activity of the thyroid gland is stimulated by food availability via leptin-induced TRH/TSH expression. Here we show that…